Edgewise Therapeutics grants 16,377 stock options

Edgewise Therapeutics director Arlene Morris received a grant of stock options covering 16,377 shares of common stock.

Rhea-AI Filing Summary

Edgewise Therapeutics director Arlene Morris received a grant of stock options covering 16,377 shares of common stock. The options have an exercise price of $35.59 per share and expire on June 5, 2036. According to the terms, 100% of these options will vest on the earlier of June 5, 2027 or the business day before the company’s 2027 annual meeting of stockholders. Following this grant, Morris holds stock options for 16,377 underlying shares directly.

Insider Trade Summary

Grant/Award: 16,377 shares

Grant/Award 1 txn

Insider Morris Arlene

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	16,377	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 16,377 contracts (Direct)

Footnotes (1)

1. F1. 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.

Key Figures

Options granted: 16,377 options Exercise price: $35.59 per share Expiration date: June 5, 2036 +3 more

6 metrics

Options granted 16,377 options Stock Option (Right to Buy) grant to director

Exercise price $35.59 per share Exercise price for the stock options

Expiration date June 5, 2036 Option expiration

Underlying shares 16,377 shares Common stock underlying the options

Post-grant derivative holdings 16,377 options Total options held following transaction

Vesting date trigger June 5, 2027 Latest vesting date for 100% of options

Key Terms

Stock Option (Right to Buy), exercise price, vesting, annual meeting of stockholder

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 35.5900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"100% of the Stock Options granted on June 5, 2026 will become vested"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholder financial

"business day prior to the 2027 annual meeting of stockholder"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Edgewise Therapeutics (EWTX) director Arlene Morris report in this Form 4?

Arlene Morris reported receiving stock options for 16,377 shares of Edgewise Therapeutics common stock. The options were granted at an exercise price of $35.59 per share as part of her director compensation, with all shares subject to future vesting conditions.

What are the key terms of the Arlene Morris stock option grant at Edgewise Therapeutics (EWTX)?

The grant covers 16,377 options to buy Edgewise Therapeutics common stock at $35.59 per share, expiring on June 5, 2036. These options are compensation-related and were awarded directly to Morris rather than being purchased in the open market.

When do Arlene Morris’s Edgewise Therapeutics (EWTX) stock options vest?

All 16,377 options granted to Arlene Morris vest 100% on the earlier of June 5, 2027 or the business day prior to Edgewise Therapeutics’ 2027 annual meeting of stockholders, aligning vesting with her board service period and the company’s governance calendar.

Did Arlene Morris buy or sell Edgewise Therapeutics (EWTX) shares in this Form 4?

No open-market buy or sell occurred; Morris received a grant of stock options. The Form 4 reflects a compensation-related award, not a market transaction, so it does not represent a discretionary purchase or sale of existing Edgewise Therapeutics common shares.

How many Edgewise Therapeutics (EWTX) options does Arlene Morris hold after this grant?

After this reported grant, Arlene Morris holds stock options representing 16,377 underlying shares directly. This figure reflects the full amount of the new award, since her reported total derivative holdings following the transaction equal the number of options granted.

What is the expiration date of Arlene Morris’s Edgewise Therapeutics (EWTX) stock options?

The stock options granted to Arlene Morris expire on June 5, 2036. After that date, any unexercised options become worthless, so Morris would need to exercise vested options before the expiration to acquire Edgewise Therapeutics common shares at the set exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 04:46 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morris Arlene

(Last) (First) (Middle)

C/O 1715 38TH STREET

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$35.59	06/05/2026		A		16,377		06/02/2027(1)	06/05/2036	Common Stock	16,377	$0.00	16,377	D

Explanation of Responses:

1. 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.

Remarks:

	/s/ John R. Moore, Attorney-in-Fact for Morris Arlene	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)